A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies
- 8 Downloads
We proposed here a minimal physiologically based pharmacokinetic (mPBPK) model for a group of novel engineered antibodies in mice and humans. These antibodies are designed with altered binding properties of their Fc domain with neonatal Fc receptor (FcRn) or the Fab domain with their cognate targets (recycling antibodies) in acidic endosomes. To enable simulations of such binding features in the change of antibody pharmacokinetics and its target suppression, we nested an endothelial endosome compartment in parallel with plasma compartment based on our previously established mPBPK model. The fluid-phase pinocytosis rate from plasma to endothelial endosomes was reflected by the clearance of antibodies in FcRn dysfunctional humans or FcRn-knockout mice. The endosomal recycling rate of FcRn-bound antibodies was calculated based on the reported endosomal transit time. The nonspecific catabolism in endosomes was fitted using pharmacokinetic data of a human wild-type IgG1 adalimumab in humans and B21M in human FcRn (hFcRn) transgenic mice. The developed model adequately predicted the pharmacokinetics of infliximab, motavizumab, and an Fc variant of motavizumab in humans and the pharmacokinetics of bevacizumab, an Fc variant of bevacizumab, and a recycling antibody PH-IgG1 and its non-pH dependent counterpart NPH-IgG1 in hFcRn transgenic mice. Our proposed model provides a platform for evaluation of the pharmacokinetics and disposition behaviors of Fc-engineered antibodies and recycling antibodies.
KEY WORDSendosome FcRn mPBPK model pharmacokinetics recycling antibody
This work was supported by grants from NIH (R35 GM119661).
Compliance with Ethical Standards
Conflict of Interest
F. Rode is an employee of Novo Nordisk, Denmark.
- 5.Wani MA, Haynes LD, Kim J, Bronson CL, Chaudhury C, Mohanty S, et al. Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene. Proc Natl Acad Sci U S A. 2006;103(13):5084–9. https://doi.org/10.1073/pnas.0600548103.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem. 2010;285(7):4826–36. https://doi.org/10.1074/jbc.M109.081828.CrossRefPubMedGoogle Scholar
- 11.Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013;57(12):6147–53. https://doi.org/10.1128/AAC.01285-13.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. MAbs. 2013;5(3):397–405. https://doi.org/10.4161/mabs.23836.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25(6):1700–21.CrossRefPubMedGoogle Scholar
- 22.Olszewski WL, Pazdur J, Kubasiewicz E, Zaleska M, Cooke CJ, Miller NE. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes. Arthritis Rheum. 2001;44(3):541–9. https://doi.org/10.1002/1529-0131(200103)44:3<541::AID-ANR102>3.0.CO;2-6.CrossRefPubMedGoogle Scholar
- 24.Proetzel G, Wiles MV. Mouse models for drug discovery. Methods and protocols. Second edition. Anticancer Res. 2016;36(8):4371. https://doi.org/10.1007/978-1-4939-3661-8.
- 29.Ng CM, Fielder PJ, Jin J, Deng R. Mechanism-based competitive binding model to investigate the effect of neonatal fc receptor binding affinity on the pharmacokinetic of humanized anti-VEGF monoclonal IgG1 antibody in Cynomolgus monkey. AAPS J. 2016;18(4):948–59. https://doi.org/10.1208/s12248-016-9911-4.CrossRefPubMedGoogle Scholar
- 30.Ferl GZ, Wu AM, DiStefano JJ 3rd. A predictive model of therapeutic monoclonal antibody dynamics and regulation by the neonatal Fc receptor (FcRn). Ann Biomed Eng. 2005;33(11):1640–52. https://doi.org/10.1007/s10439-005-7410-3.
- 34.Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, et al. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs. 2015;7(2):331–43. https://doi.org/10.1080/19420862.2015.1008353.CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Chen X, Jiang X, Jusko WJ, Zhou H, Wang W. Minimal physiologically-based pharmacokinetic (mPBPK) model for a monoclonal antibody against interleukin-6 in mice with collagen-induced arthritis. J Pharmacokinet Pharmacodyn. 2016;43(3):291–304. https://doi.org/10.1007/s10928-016-9472-2.CrossRefPubMedGoogle Scholar
- 37.Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184(4):1968–76. https://doi.org/10.4049/jimmunol.0903296.CrossRefPubMedGoogle Scholar